Back to today’s briefing

Story perspectives

Novo Nordisk Launches $499 Ozempic for Diabetes Patients

8/26/2025

25 5

Summary

Story summary

Novo Nordisk will offer Ozempic for $499 monthly to eligible cash-paying type 2 diabetes patients in the U.S.
This announcement follows a price reduction for Wegovy, intended for weight loss.
The program includes partnerships with GoodRx and NovoCare pharmacy.
President Trump noted considerable price differences between the U.S. and other nations.

1 of 1

Story summary

Novo Nordisk will offer Ozempic for $499 monthly to eligible cash-paying type 2 diabetes patients in the U.S.
This announcement follows a price reduction for Wegovy, intended for weight loss.
The program includes partnerships with GoodRx and NovoCare pharmacy.
President Trump noted considerable price differences between the U.S. and other nations.